Skip to main content
. 2007 Mar 27;7:13. doi: 10.1186/1471-230X-7-13

Table 4.

Major side effects observed during the intravenous and oral phases of CsA administration

Adverse event Outcome N (%) Treatment Phase
Pulmonary Embolism Death 1 (2.5%) Intravenous
>33% ↑ creatinine Dose maintained 7 (17%) Oral
2 × creatinine Dose reduced 1 (2.5%) Oral
Biliary sludge Drug discontinued 2 (5%) Intravenous
↑ liver function tests Dose maintained 2 (5%) Intravenous
Seizures Dose maintained 1 (2.5%) Oral